Figure 3

Individual MRC % trajectories of seven patients who were enrolled while ongoing nusinersen therapy. The first data point depicts the therapy month of enrolment; the last complies with the last assessment taken before data-cut. Individual variability of motor function in patients up to month 26 can be seen, with initial increases at the beginning of the observation period in five patients, succeeded by a predominantly stable period in three patients and a more variable trajectory in two patients. Comparing baseline to last assessment, improvement of motor function could be witnessed in most patients. Non-ambulatory patients presented with a total MRC % under 60% in the lower half of the graph.